Opening up new horizons for psychiatric genetics in the Russian Federation: moving toward a national consortium.


Journal

Molecular psychiatry
ISSN: 1476-5578
Titre abrégé: Mol Psychiatry
Pays: England
ID NLM: 9607835

Informations de publication

Date de publication:
08 2019
Historique:
received: 11 08 2018
accepted: 31 12 2018
revised: 27 12 2018
pubmed: 22 1 2019
medline: 10 3 2020
entrez: 22 1 2019
Statut: ppublish

Résumé

We provide an overview of the recent achievements in psychiatric genetics research in the Russian Federation and present genotype-phenotype, population, epigenetic, cytogenetic, functional, ENIGMA, and pharmacogenetic studies, with an emphasis on genome-wide association studies. The genetic backgrounds of mental illnesses in the polyethnic and multicultural population of the Russian Federation are still understudied. Furthermore, genetic, genomic, and pharmacogenetic data from the Russian Federation are not adequately represented in the international scientific literature, are currently not available for meta-analyses and have never been compared with data from other populations. Most of these problems cannot be solved by individual centers working in isolation but warrant a truly collaborative effort that brings together all the major psychiatric genetic research centers in the Russian Federation in a national consortium. For this reason, we have established the Russian National Consortium for Psychiatric Genetics (RNCPG) with the aim to strengthen the power and rigor of psychiatric genetics research in the Russian Federation and enhance the international compatibility of this research.The consortium is set up as an open organization that will facilitate collaborations on complex biomedical research projects in human mental health in the Russian Federation and abroad. These projects will include genotyping, sequencing, transcriptome and epigenome analysis, metabolomics, and a wide array of other state-of-the-art analyses. Here, we discuss the challenges we face and the approaches we will take to unlock the huge potential that the Russian Federation holds for the worldwide psychiatric genetics community.

Identifiants

pubmed: 30664668
doi: 10.1038/s41380-019-0354-z
pii: 10.1038/s41380-019-0354-z
pmc: PMC6756082
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1099-1111

Références

Rogaev E. Academic psychiatry in Russia: new times, new challenges. Mol Psychiatry. 2004;9:975–6.
pubmed: 15505613 doi: 10.1038/sj.mp.4001603
Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D, et al. Common variants conferring risk of schizophrenia. Nature. 2009;460:744–7.
pubmed: 19571808 pmcid: 3077530 doi: 10.1038/nature08186
Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium. Genome-wide association study identifies five new schizophrenia loci. Nat Genet. 2011;43:969–76.
doi: 10.1038/ng.940
Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511:421–7.
pmcid: 4112379 doi: 10.1038/nature13595
Mühleisen TW, Leber M, Schulze TG, Strohmaier J, Degenhardt F, Treutlein J, et al. Genome-wide association study reveals two new risk loci for bipolar disorder. Nat Commun. 2014;5:3339.
pubmed: 24618891 doi: 10.1038/ncomms4339
Pardiñas AF, Holmans P, Pocklington AJ, Escott-Price V, Ripke S, Carrera N et al. Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection. Nat Genet 2018. https://doi.org/10.1038/s41588-018-0059-2 .
pubmed: 29483656 pmcid: 5918692 doi: 10.1038/s41588-018-0059-2
Stepanov VA, Marusin AV, Simonova K. Genetic variability in common mental and neurological disorders in North Eurasia. Clin Biochem. 2011; 44, Supplement: S27-S28.
Golenkina SA, Gol’tsov AIu, Kuznetsova IL, Grigorenko AP, Andreeva TV, Reshetov DA, et al. Analysis of clusterin gene (CLU/APOJ) polymorphism in Alzheimer’s disease patients and in normal cohorts from Russian populations. Mol Biol (Mosk). 2010;44:620–6.
doi: 10.1134/S0026893310040072
Nizamutdinov II, Andreeva TV, Stepanov VA, Marusin AV, Rogaev EI, Zasedatelev AS, et al. Biochip for determination of genetic markers of sporadic Alzheimer’s disease in the Russian Slavic population. Mol Biol (Mosk). 2013;47:949–58.
doi: 10.1134/S0026893313060101
Stepanov VA, Bocharova AV, Marusin AV, Zhukova NG, Alifirova VM, Zhukova IA. Replicative association analysis of genetic markers of cognitive traits with Alzheimer’s disease in a Russian population. Mol Biol (Mosk). 2014;48:952–62.
doi: 10.1134/S0026893314060168
Stepanov VA, Bocharova AV, Saduakassova KZ, Marusin AV, Koneva LA, Vagaitseva KV, et al. Replicative study of susceptibility to childhood-onset schizophrenia in Kazakhs. Genetika. 2015;51:227–35.
pubmed: 25966588
Bocharova AV, Stepanov VA, Marusin AV, Kharkov VN, Vagaitseva KV, Fedorenko OY, et al. Association study of genetic markers of schizophrenia and its cognitive endophenotypes. Genetika. 2017;53:100–8.
pubmed: 29372809
Gareeva AE, Zakirov DF, Khusnutdinova EK. Association polymorphic variants of GRIN2B gene with paranoid schizophrenia and response to common neuroleptics in Russians and Tatars from Bashkortostan Republic. Russ J Genet. 2013;49:962–8.
doi: 10.1134/S1022795413080024
Gareeva AE, Traks T, Koks S, Khusnutdinova EK. The Role of Neurotrophins and Neurexins Genes in the Risk of Paranoid Schizophrenia in Russians and Tatars. Russ J Genet. 2015;51:799–811.
doi: 10.1134/S102279541506006X
Gareeva AE, Khusnutdinova EK. Glutamate receptors genes polymorphism and the risk of paranoid schizophrenia in Russians and Tatars from the Republic of Bashkortostan. Mol Biol. 2014;48:671–80.
doi: 10.1134/S0026893314050033
Gareeva AE, Zakirov DF, Valinurov RG, Khusnutdinova EK. Polymorphism of RGS2 gene: genetic markers of risk for schizophrenia and pharmacogenetic markers of typical neuroleptics efficiency. Mol Biol. 2013;47:814–20.
doi: 10.1134/S0026893313060046
Galaktionova DYu, Gareeva AE, Khusnutdinova EK, Nasedkina TV. The association of polymorphisms in SLC18A1, TPH1 and RELN genes with risk of paranoid schizophrenia. Mol Biol. 2014;48:546–55.
doi: 10.1134/S0026893314030042
Noskova T, Pivac N, Nedic G, Kazantseva A, Gaysina D, Faskhutdinova G, et al. Ethnic differences in the serotonin transporter polymorphism (5-HTTLPR) in several European populations. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:1735–9.
pubmed: 18700161 doi: 10.1016/j.pnpbp.2008.07.012
Noskova TG, Kazantseva AV, Gareeva AE, Gaĭsina DA, Tuktarova SU, Khusnutdinova EK. association of several polymorphic loci of serotoninergic genes with unipolar depression. Russ J Genet. 2009;45:742–8.
doi: 10.1134/S1022795409060143
Fedorenko OYu, Rudikov EV, Gavrilova VA, Boiarko EG, Semke AV, Ivanova SA. Association of (N251S)-PIP5K2A with schizophrenic disorders: a study of the Russian population of Siberia. Zh Nevrol Psikhiatr Im S S Korsakova. 2013;113:58–61.
pubmed: 23739505
Zhilyaeva TV, Sergeeva AV, Blagonravova AS, Kasimova LN. Psychopathological characteristics and social functioning of the schizophrenic patients with the T allele of the MTHFR677C>T polymorphism. Zh Nevrol Psikhiatr Im S S Korsakova. 2016;116:5–11.
pubmed: 28091495 doi: 10.17116/jnevro20161161115-11
Zhilyaeva TV, Sergeeva AV, Blagonravova AS, Kasimova LN, Kuznetsov KV, Golovanova VI, et al. Association study of methylenetetrahydrofolate reductase genetic polymorphism 677C>T with schizophrenia in hospitalized patients in population of European Russia. Asian J Psychiatr. 2018;32:29–33.
pubmed: 29202425 doi: 10.1016/j.ajp.2017.11.027
Alfimova MV, Monakhov MV, Abramova LI, Golubev SA, Golimbet VE. Polymorphism of serotonin receptor genes (5-HTR2A) and dysbindin (DTNBP1) and individual components of short-term verbal memory processes in schizophrenia. Neurosci Behav Physiol. 2010;40:934–40.
pubmed: 20683774 doi: 10.1007/s11055-010-9348-7
Golimbet VE, Alfimova MV, Gritsenko IK, Lezheiko TV, Lavrushina OM, Abramova LI, et al. Association between a synaptosomal protein (SNAP-25) gene polymorphism and verbal memory and attention in patients with endogenous psychoses and mentally healthy subjects. Neurosci Behav Physiol. 2010;40:461–5.
pubmed: 20333500 doi: 10.1007/s11055-010-9280-x
Golimbet VE, Lebedeva IS, Korovaitseva GI, Lezheiko TV, Abramova LI, Kaleda VG, et al. The Cys allele (the Ser311Cys polymorphism) of the dopamine D2 receptor is associated with schizophrenia and impairments to selective attention in patients. Neurosci Behav Physiol. 2011;41:22–24.
doi: 10.1007/s11055-010-9372-7
Alfimova MV, Golimbet VE, Korovaitseva GI, Abramova LI, Kaleda VG. Association between serotonin receptor 2C gene Cys23Ser polymorphism and social behavior in schizophrenia patients and healthy individuals. Russ J Genet. 2015;51:198–203.
doi: 10.1134/S1022795415010020
Golimbet V, Alfimova M, Abramova L, Kaleda V, Gritsenko I. Arginine vasopressin 1a receptor RS3 promoter microsatellites in schizophrenia: a study of the effect of the “risk” allele on clinical symptoms and facial affect recognition. Psychiatry Res. 2015;225:739–40.
pubmed: 25529259 doi: 10.1016/j.psychres.2014.11.043
Alfimova MV, Golimbet VE, Lezheiko TV, Kondrat’ev NV. Association of -717A>G Polymorphism in the C-Reactive Protein Gene (CRP) with Schizotypal Personality Traits. Bull Exp Biol Med. 2016;162:86–88.
pubmed: 27878726 doi: 10.1007/s10517-016-3552-6
Alfimova MV, Korovaitseva GI, Lezheiko TV, Golimbet VE. Interaction Effects of Season of Birth and Cytokine Genes on Schizotypal Traits in the General Population. Schizophr Res Treat. 2017;2017:5763094.
Golimbet VE, Alfimova MV, Korovaitseva GI, Lezheiko TV. Modulating effect of Val66Met polymorphism of brain-derived neurotrophic factor gene on clinical and psychological characteristics of patients with schizophrenia. Mol Biol. 2014;48:69–74.
doi: 10.1134/S0026893314010038
Golimbet V, Alfimova M, Abramova L, Kaleda V, Gritsenko I. Arginine vasopressin 1a receptor RS3 promoter microsatellites in schizophrenia: a study of the effect of the “risk” allele on clinical symptoms and facial affect recognition. Psychiatry Res. 2015;225:739–40.
pubmed: 25529259 doi: 10.1016/j.psychres.2014.11.043
Golimbet V, Korovaitseva G, Lezheiko T, Abramova LI, Kaleda VG. The serotonin transporter gene 5-HTTLPR polymorphism is associated with affective psychoses but not with schizophrenia: A large-scale study in the Russian population. J Affect Disord. 2017;208:604–9.
pubmed: 28029428 doi: 10.1016/j.jad.2016.10.020
Lappalainen J, Krupitsky E, Remizov M, Pchelina S, Taraskina A, Zvartau E, et al. Association between alcoholism and gamma-amino butyric acid alpha2 receptor subtype in a Russian population. Alcohol Clin Exp Res. 2005;29:493–8.
pubmed: 15834213 doi: 10.1097/01.ALC.0000158938.97464.90
Zhang H, Luo X, Kranzler HR, Lappalainen J, Yang BZ, Krupitsky E, et al. Association between two mu-opioid receptor gene (OPRM1) haplotype blocks and drug or alcohol dependence. Hum Mol Genet. 2006;15:807–19.
pubmed: 16476706 doi: 10.1093/hmg/ddl024
Lappalainen J, Krupitsky E, Kranzler HR, Luo X, Remizov M, Pchelina S, et al. Mutation screen of the GAD2 gene and association study of alcoholism in three populations. Am J Med Genet B Neuropsychiatr Genet. 2007;144B:183–92.
pubmed: 17034009 doi: 10.1002/ajmg.b.30377
Ovchinnikov IV, Druzina E, Ovtchinnikova O, Zagorovskaya T, Nebarakova T, Anokhina IP. Polymorphism of dopamine D2 and D4 receptor genes and Slavic-surnamed alcoholic patients. Addict Biol. 1999;4(4):399–404.
pubmed: 20575808 doi: 10.1080/13556219971380
Kibitov AO, Voskoboeva EIu, Brodianskiĭ VM, Chuprova NA, Smirnova EV. Association study of the Val158Met polymorphism of the catechol-O-methyltransferase gene and alcoholism and heroin dependence: the role of a family history. Zh Nevrol Psikhiatr Im S S Korsakova. 2010;110:84–88.
pubmed: 20517217
Ivashchenko DV, Shuvalov SA, Chuprova NA, Kibitov AO. The association of polymorphisms in DAT (40 bp VNTR, C>T 3’UTR) and DBH (-1021 C/T) genes with the severe complications of alcohol withdrawal state. Psychiatr Genet. 2015;25:268–9.
pubmed: 26313930 doi: 10.1097/YPG.0000000000000101
Kibitov AO, Ivashchenko DV, Brodyansky VM, Chuprova NA, Shuvalov SA. Combination of DAT and DBH gene polymorphisms with a family history of alcohol use disorders increases the risk of withdrawal seizures and delirium tremens during alcohol withdrawal in alcohol-dependent men. Zh Nevrol Psikhiatr Im S S Korsakova. 2016;116:68–80.
pubmed: 28139629 doi: 10.17116/jnevro201611612168-80
Stepanov VA, Marusin AV, Vagaitseva KV, Bocharova AV, Makeeva OA. Genetic Variants in CSMD1 Gene Are Associated with Cognitive Performance in Normal Elderly Population. Genet Res Int. 2017;2017:6293826.
pubmed: 29379655 pmcid: 5742897
Stepanov VA, Vagaytseva K, Bocharova A, Marusin A, Markova V, Minaycheva L, et al. Analysis of association of genetic markers in LUZP2 and FXBO40 genes with the normal variability in cognitive performance in the elderly. Int J Alzheimers Dis. 2018; Article ID 2686045, 7.
Bocharova AV, Vagaitseva KV, Makeeva OA, Marusin AV, Stepanov VA. Frequencies of alleles, genotypes and haplotypes of two polymorphisms in the clusterin gene in the Russian elderly population categorized by cognitive performance. Data Brief. 2017;16:775–9.
pubmed: 29276745 pmcid: 5738205 doi: 10.1016/j.dib.2017.12.019
Levchenko A, Davtian S, Petrova N, Malashichev Y. Sequencing of five left-right cerebral asymmetry genes in a cohort of schizophrenia and schizotypal disorder patients from Russia. Psychiatr Genet. 2014;24:75–80.
pubmed: 24322325 doi: 10.1097/YPG.0000000000000021
Beaulieu JM, Gainetdinov RR, Caron MG. Akt/GSK3 signaling in the action of psychotropic drugs. Annu Rev Pharmacol Toxicol. 2009;49:327–47. (2009)
pubmed: 18928402 doi: 10.1146/annurev.pharmtox.011008.145634
Levchenko A, Davtian S, Freylichman O, Zagrivnaya M, Kostareva A, Malashichev Y. Beta-catenin in schizophrenia: possibly deleterious novel mutation. Psychiatry Res. 2015;228:843–8.
pubmed: 26027441 doi: 10.1016/j.psychres.2015.05.014
Kashevarova AA, Nazarenko LP, Skryabin NA, Salyukova OA, Chechetkina NN, Tolmacheva EN, et al. Array CGH analysis of a cohort of Russian patients with intellectual disability. Gene. 2014;536:145–50.
pubmed: 24291026 doi: 10.1016/j.gene.2013.11.029
Kashevarova AA, Nazarenko LP, Schultz-Pedersen S, Skryabin NA, Salyukova OA, Chechetkina NN, et al. Single gene microdeletions and microduplication of 3p26.3 in three unrelated families: CNTN6 as a new candidate gene for intellectual disability. Mol Cytogenet. 2014;7:97.
pubmed: 25606055 pmcid: 4299808 doi: 10.1186/s13039-014-0097-0
Kashevarova AA, Belyaeva EO, Nikonov AM, Plotnikova OV, Skryabin NA, Nikitina TV, et al. Compound phenotype in a girl with r(22), concomitant microdeletion 22q13.32-q13.33 and mosaic monosomy 22. Mol Cytogenet. 2018;11:26.
pubmed: 29736186 pmcid: 5923029 doi: 10.1186/s13039-018-0375-3
Lebedev IN, Nazarenko LP, Skryabin NA, Babushkina NP, Kashevarova AA. A de novo microtriplication at 4q21.21-q21.22 in a patient with a vascular malignant hemangioma, elongated sigmoid colon, developmental delay, and absence of speech. Am J Med Genet A. 2016;170A:2089–96.
doi: 10.1002/ajmg.a.37754
Iourov IY, Vorsanova SG, Kurinnaia OS, Zelenova MA, Silvanovich AP, Yurov YB. Molecular karyotyping by array CGH in a Russian cohort of children with intellectual disability, autism, epilepsy and congenital anomalies. Mol Cytogenet. 2012;5(1):46.
pubmed: 23272938 pmcid: 3547809 doi: 10.1186/1755-8166-5-46
Iourov IY, Vorsanova SG, Korostelev SA, Zelenova MA, Yurov YB. Long contiguous stretches of homozygosity spanning shortly the imprinted loci are associated with intellectual disability, autism and/or epilepsy. Mol Cytogenet. 2015;8(1):77.
pubmed: 26478745 pmcid: 4608298 doi: 10.1186/s13039-015-0182-z
Kennedy JL, Basile VS, Macciardi FM, Detera-Wadleigh S, Evans KL, Holmans PA, et al. Chromosome 4 workshop summary: Sixth World Congress on Psychiatric Genetics, Bonn, Germany, October 6–10, 1998. Am J Med Genet. 1999;88:224–8.
pubmed: 10374735 doi: 10.1002/(SICI)1096-8628(19990618)88:3<224::AID-AJMG3>3.0.CO;2-J
Yurov YB, Vostrikov VM, Vorsanova SG, Monakhov VV, Iourov IY. Multicolor fluorescent in situ hybridization on post-mortem brain in schizophrenia as an approach for identification of low-level chromosomal aneuploidy in neuropsychiatric diseases. Brain Dev. 2001;23:S186–190.
pubmed: 11738870 doi: 10.1016/S0387-7604(01)00363-1
Iourov IY, Vorsanova SG, Yurov YB. Chromosomal variation in mammalian neuronal cells: known facts and attractive hypotheses. Int Rev Cytol. 2006;249:143–91.
pubmed: 16697283 doi: 10.1016/S0074-7696(06)49003-3
Yurov YB, Vorsanova SG, Iourov IY, Demidova IA, Beresheva AK, Kravetz VS, et al. Unexplained autism is frequently associated with low-level mosaic aneuploidy. J Med Genet. 2007;44:521–5.
pubmed: 17483303 pmcid: 2597925 doi: 10.1136/jmg.2007.049312
Yurov YB, Iourov IY, Vorsanova SG, Demidova IA, Kravetz VS, Beresheva AK, et al. The schizophrenia brain exhibits low-level aneuploidy involving chromosome 1. Schizophr Res. 2008;98:139–47.
pubmed: 17889509 doi: 10.1016/j.schres.2007.07.035
Iourov IY, Vorsanova SG, Liehr T, Yurov YB. Aneuploidy in the normal, Alzheimer’s disease and ataxia-telangiectasia brain: differential expression and pathological meaning. Neurobiol Dis. 2009;34:212–20.
pubmed: 19344645 doi: 10.1016/j.nbd.2009.01.003
Iourov IY, Vorsanova SG, Liehr T, Kolotii AD, Yurov YB. Increased chromosome instability dramatically disrupts neural genome integrity and mediates cerebellar degeneration in the ataxia-telangiectasia brain. Hum Mol Genet. 2009;18:2656–69.
pubmed: 19414482 doi: 10.1093/hmg/ddp207
Yurov YB, Vorsanova SG, Iourov IY. The DNA replication stress hypothesis of Alzheimer’s disease. Sci World J. 2011;11:2602–12.
doi: 10.1100/2011/625690
Yurov YB, Vorsanova SG, Liehr T, Kolotii AD, Iourov IY. X chromosome aneuploidy in the Alzheimer’s disease brain. Mol Cytogenet. 2014;7:20.
pubmed: 24602248 pmcid: 3995993 doi: 10.1186/1755-8166-7-20
Yurov YB, Vorsanova SG, Demidova IA, Vorsanova SG, Demidova IA, Kolotii AD, et al. Mosaic brain aneuploidy in mental illnesses: an association of low-level post-zygotic aneuploidy with schizophrenia and comorbid psychiatric disorders. Curr Genom. 2018;19:163–72.
doi: 10.2174/1389202918666170717154340
Iourov IY, Vorsanova SG, Voinova VY, Yurov YB. 3p22.1p21.31 microdeletion identifies CCK as Asperger syndrome candidate gene and shows the way for therapeutic strategies in chromosome imbalances. Mol Cytogenet. 2015;8:82.
pubmed: 26523151 pmcid: 4628252 doi: 10.1186/s13039-015-0185-9
Alfimova MV, Kondratiev NV, Golov AK, Golimbet VE. Methylation of the reelin gene promoter in peripheral blood and its relationship with cognitive performance of schizophrenic patients. Mol Biol. 2018;5:676–85.
doi: 10.1134/S0026893318050023
Fedorenko O, Strutz-Seebohm N, Henrion U, Ureche O, Seebohm G, Lang FA, et al. Schizophrenia-linked mutation in PIP5K2A fails to activate neuronal M-channels in Xenopus oocytes. Psychopharmacol (Berl). 2008;199:47–54.
doi: 10.1007/s00213-008-1095-x
Fedorenko O, Tang C, Sopjani M, Föller M, Gehring EM, Strutz-Seebohm N, et al. PIP5K2A-dependent regulation of excitatory amino acid transporter EAAT3. Psychopharmacol (Berl). 2009;206:429–35.
doi: 10.1007/s00213-009-1621-5
Gridina MM, Matveeva NM, Fishman VS, Menzorov AG, Kizilova HA, Beregovoy NA, et al. Allele-specific biased expression of the CNTN6 gene in iPS cell-derived neurons from a patient with intellectual disability and 3p26.3 microduplication involving the CNTN6 gene. Mol Neurobiol 2018;55:6533–46.
pubmed: 29327201 doi: 10.1007/s12035-017-0851-5
Schmaal L, Hibar DP, Sämann PG, Hall GB, Baune BT, Jahanshad N, et al. Cortical abnormalities in adults and adolescents with major depression based on brain scans from 20 cohorts worldwide in the ENIGMA Major Depressive Disorder Working Group. Mol Psychiatry. 2017;22:900–9.
doi: 10.1038/mp.2016.60 pubmed: 27137745
van Erp TGM, Walton E, Hibar DP, Schmaal L, Jiang W, Glahn DC, et al. Cortical brain abnormalities in 4474 individuals with Schizophrenia and 5098 Control Subjects Via The Enhancing Neuro Imaging Genetics Through Meta Analysis (ENIGMA) Consortium. Biol Psychiatry. 2018; pii: S0006-3223(18)31517-8. https://doi.org/10.1016/j.biopsych.2018.04.023 .
pubmed: 29960671 doi: 10.1016/j.biopsych.2018.04.023 pmcid: 6177304
Kong XZ, Mathias SR, Guadalupe T, ENIGMA Laterality Working Group, Glahn DC, Franke B, et al. Mapping cortical brain asymmetry in 17,141 healthy individuals worldwide via the ENIGMA Consortium. Proc Natl Acad Sci USA. 2018;115(22):E5154–E5163.
pubmed: 29764998 doi: 10.1073/pnas.1718418115 pmcid: 5984496
Taraskina AE, Nasyrova RF, Zabotina AM, Sosin DN, Sosina КА, Ershov EE, et al. Potential diagnostic markers of olanzapine efficiency for acute psychosis: a focus on peripheral biogenic amines. BMC Psychiatry. 2017;17:394.
pubmed: 29221470 pmcid: 5723030 doi: 10.1186/s12888-017-1562-1
Gareeva AE, Kinyasheva KO, Galaktionova DYu, Sabirov ET, Valinurov RG, Chudinov AV, et al. Polymorphism of brain neurotransmitter system genes: search for pharmacogenetic markers of haloperidol efficiency in Russians and Tatars. Mol Biol. 2015;49:858–66.
doi: 10.1134/S0026893315050076
Kurylev AA, Brodyansky VM, Andreev BV, Kibitov AO, Limankin OV, Mosolov SN. The combined effect of CYP2D6 and DRD2 TAQ1A polymorphisms on the antipsychotics daily doses and hospital stay duration in schizophrenia inpatients (observational naturalistic study). Psychiatr Danub. 2018;30(2):160–89.
Zastrozhin MS, Brodyansky VM, Skryabin VY, Grishina EA, Ivashchenko DV, Ryzhikova KA, et al. Pharmacodynamic genetic polymorphisms affect adverse drug reactions of haloperidol in patients with alcohol-use disorder. Pharmgenomics Pers Med. 2017;10:209–15.
pubmed: 28744152 pmcid: 5511016
Losenkov IS, Vyalova NM, Simutkin GG, Bokhan NA, Ivanova SA. An association of AKT1 gene polymorphism with antidepressant treatment response. World J Biol Psychiatry. 2016;17:239–42.
pubmed: 26515520 doi: 10.3109/15622975.2015.1112921
Levchenko A, Losenkov IS, Vyalova NM, Simutkin GG, Bokhan NA, Wilffert B, et al. The functional variant rs334558 of GSK3B is associated with remission in patients with depressive disorders. Pharmgenomics Pers Med. 2018;11:121–6.
pubmed: 30050316 pmcid: 6055890
Krupitsky ЕМ, Kibitov АО, Blokhina ЕА, Verbitskaya ЕV, Brodyansky V, Alekseeva NP, et al. Stabilization of remission in patients with opioid dependence with naltrexone implant: a pharmacogenetic approach. Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115:14–23.
doi: 10.17116/jnevro20151154214-23
Kibitov АО, Krupitsky ЕМ, Blokhina ЕА, Verbitskaya ЕV, Brodyansky VМ, Alekseeva NP, et al. A pharmacogenetic analysis of dopaminergic and opioidergic genes in opioid addicts treated with the combination of naltrexone and guanfacine. Zh Nevrol Psikhiatr Im S S Korsakova. 2016;116:36–48.
doi: 10.17116/jnevro201611611236-48
Barbitoff YA, Bezdvornykh IV, Polev DE, Serebryakova EA, Glotov AS, Glotov OS, et al. Catching hidden variation: systematic correction of reference minor alleles in clinical variant calling. Genet Med. 2018;20:360–4.
pubmed: 29155419 doi: 10.1038/gim.2017.168
Zhernakova DV, Kliver S, Cherkasov N, Tamazian G, Rotkevich M, Krasheninnikova K, et al. Analytical “bake-off” of whole genome sequencing quality for the Genome Russia project using a small cohort for autoimmune hepatitis. PLoS ONE. 2018;13(7):e0200423.
pubmed: 29995946 pmcid: 6040705 doi: 10.1371/journal.pone.0200423
Leo D, Sukhanov I, Zoratto F, Illiano P, Caffino L, Sanna F, et al. Pronounced hyperactivity, cognitive dysfunctions, and BDNF dysregulation in dopamine transporter knock-out Rats. J Neurosci. 2018;38:1959–72.
pubmed: 29348190 pmcid: 5824739 doi: 10.1523/JNEUROSCI.1931-17.2018
Hou L, Heilbronner U, Degenhardt F, Adli M, Akiyama K, Akula N, et al. Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study. Lancet. 2016;387:1085–93.
pubmed: 26806518 pmcid: 4814312 doi: 10.1016/S0140-6736(16)00143-4
Al Hadithy AFY, Ivanova SA, Pechlivanoglou P, Semke A, Fedorenko O, Kornetova E, et al. Tardive dyskinesia and DRD3, HTR2A and HTR2C gene polymorphisms in Russian psychiatric inpatients from Siberia. Progress Neuropsychopharmacol Biol Psychiatry. 2009;33:475–81.
doi: 10.1016/j.pnpbp.2009.01.010
Al Hadithy AF, Ivanova SA, Pechlivanoglou P, Wilffert B, Semke A, Fedorenko O, et al. Missense polymorphisms in three oxidative-stress enzymes (GSTP1, SOD2, and GPX1) and dyskinesias in Russian psychiatric inpatients from Siberia. Hum Psychopharmacol. 2010;25:84–91.
pubmed: 20041472 doi: 10.1002/hup.1087
Ivanova SA, Loonen AJM, Pechlivanoglou P, Freidin MB, Al Hadithy AFY, Rudikov EV, et al. NMDA receptor genotypes associated with the vulnerability to develop dyskinesia. Translational. Psychiatry. 2012;2:e67.
Loonen AJ, Ivanova SA. New insights into the mechanism of drug-induced dyskinesia. CNS Spectr. 2013;18:15–20.
pubmed: 23593652 doi: 10.1017/S1092852912000752
Ivanova SA, Filipenko ML, Vyalova NM, Voronina EN, Pozhidaev IV, Osmanova DZ, et al. CYP1A2 and CYP2D6 gene polymorphisms in Schizophrenic patients with neuroleptic drug-induced side effects. Bull Exp Biol Med. 2016;160:687–90.
pubmed: 27021090 doi: 10.1007/s10517-016-3250-4
Ivanova SA, Geers LM, Al Hadithy AF, Pechlivanoglou P, Semke AV, Vyalova NM, et al. Dehydroepiandrosterone sulphate as a putative protective factor against tardive dyskinesia. Prog Neuropsychopharmacol Biol Psychiatry. 2014;50:172–7.
pubmed: 24389397 doi: 10.1016/j.pnpbp.2013.12.015
Ivanova SA, Toshchakova VA, Filipenko ML, Fedorenko OY, Boyarko EG, Boyko AS, et al. Cytochrome P450 1A2 gene polymorphism may diminish tardive dyskinesia by increased inducibility. World J Biol Psychiatry. 2015;16:200–5.
pubmed: 25602162 doi: 10.3109/15622975.2014.995222
Fedorenko OY, Loonen AJ, Lang F, Toshachakova VA, Boyarko EG, Semke AV et al. Association study indicates a protective role of phosphatidylinositol-4-phosphate-5-kinase against tardive dyskinesia. Int J Neuropsychopharmacol. 2014; 18: pii: pyu098.
doi: 10.1093/ijnp/pyu098
Ivanova SA, Al Hadithy AF, Brazovskaya N, Semke A, Wilffert B, Fedorenko O, et al. No involvement of the adenosine A2A receptor in tardive dyskinesia in Russian psychiatric inpatients from Siberia. Hum Psychopharmacol. 2012;27:334–7.
pubmed: 22585593 doi: 10.1002/hup.2226
Ivanova SA, Loonen AJ, Bakker PR, Freidin MB, Ter Woerds NJ, Al Hadithy AF, et al. Likelihood of mechanistic roles for dopaminergic, serotonergic and glutamatergic receptors in tardive dyskinesia: A comparison of genetic variants in two independent patient populations. SAGE Open Med. 2016;4:2050312116643673.
pubmed: 27127627 pmcid: 4834466 doi: 10.1177/2050312116643673
Ivanova SA, Osmanova DZ, Freidin MB, Fedorenko OY, Boiko AS, Pozhidaev IV, et al. Identification of 5-hydroxytryptamine receptor gene polymorphisms modulating hyperprolactinaemia in antipsychotic drug-treated patients with schizophrenia. World J Biol Psychiatry. 2017;18:239–46.
pubmed: 27654063 doi: 10.1080/15622975.2016.1224926
Fedorenko OYu, Loonen AJM, Vyalova NM, Boiko АS, Pozhidaev IV, Osmanova DZ, et al. Hyperprolactinemia and CYP2D6, DRD2 and HTR2C genes polymorphism in patients with schizophrenia. Physiol Pharmacol. 2017;21:25–33.
Ivanova SA, Osmanova DZ, Boiko AS, Pozhidaev IV, Freidin MB, Fedorenko OY, et al. Prolactin gene polymorphism (-1149G/T) is associated with hyperprolactinemia in patients with schizophrenia treated with antipsychotics. Schizophr Res. 2017;182:110–4.
pubmed: 27776952 doi: 10.1016/j.schres.2016.10.029

Auteurs

Olga Yu Fedorenko (OY)

Mental Health Research Institute, Tomsk National Research Medical Center of Russian Academy of Sciences, Tomsk, Russian Federation. f_o_y@mail.ru.
National Research Tomsk Polytechnic University, Tomsk, Russian Federation. f_o_y@mail.ru.

Vera E Golimbet (VE)

Mental Health Research Center, Moscow, Russian Federation.

Svetlana А Ivanova (SА)

Mental Health Research Institute, Tomsk National Research Medical Center of Russian Academy of Sciences, Tomsk, Russian Federation.
National Research Tomsk Polytechnic University, Tomsk, Russian Federation.

Аnastasia Levchenko (А)

Institute of Translational Biomedicine, Saint Petersburg State University, Saint Petersburg, Russian Federation.

Raul R Gainetdinov (RR)

Institute of Translational Biomedicine, Saint Petersburg State University, Saint Petersburg, Russian Federation.

Arkady V Semke (AV)

Mental Health Research Institute, Tomsk National Research Medical Center of Russian Academy of Sciences, Tomsk, Russian Federation.

German G Simutkin (GG)

Mental Health Research Institute, Tomsk National Research Medical Center of Russian Academy of Sciences, Tomsk, Russian Federation.

Аnna E Gareeva (АE)

Institute of Biochemistry and Genetics, Ufa Federal Research Center, Russian Academy of Sciences, Ufa, Russian Federation.
Federal State Educational Institution of Highest Education Bashkir State Medical University of Public Health Ministry of Russian Federation, Ufa, Russian Federation.

Аndrey S Glotov (АS)

Laboratory of Biobanking and Genomic Medicine of Institute of Translational Biomedicine, Saint Petersburg State University, Saint Petersburg, Russian Federation.

Anna Gryaznova (A)

Institute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU, Munich, Germany.

Ivan Y Iourov (IY)

Mental Health Research Center, Moscow, Russian Federation.

Evgeny M Krupitsky (EM)

V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology, Saint Petersburg, Russian Federation.

Igor N Lebedev (IN)

Research Institute of Medical Genetics, Tomsk National Research Medical Center of Russian Academy of Sciences, Tomsk, Russian Federation.

Galina E Mazo (GE)

V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology, Saint Petersburg, Russian Federation.

Vasily G Kaleda (VG)

Mental Health Research Center, Moscow, Russian Federation.

Lilia I Abramova (LI)

Mental Health Research Center, Moscow, Russian Federation.

Igor V Oleichik (IV)

Mental Health Research Center, Moscow, Russian Federation.

Yulia A Nasykhova (YA)

Laboratory of Biobanking and Genomic Medicine of Institute of Translational Biomedicine, Saint Petersburg State University, Saint Petersburg, Russian Federation.

Regina F Nasyrova (RF)

V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology, Saint Petersburg, Russian Federation.

Anton E Nikolishin (AE)

Serbsky National Medical Research Center on Psychiatry and Addictions, Moscow, Russian Federation.

Evgeny D Kasyanov (ED)

V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology, Saint Petersburg, Russian Federation.

Grigory V Rukavishnikov (GV)

V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology, Saint Petersburg, Russian Federation.

Ilgiz F Timerbulatov (IF)

Federal State Educational Institution of Highest Education Bashkir State Medical University of Public Health Ministry of Russian Federation, Ufa, Russian Federation.

Vadim M Brodyansky (VM)

Serbsky National Medical Research Center on Psychiatry and Addictions, Moscow, Russian Federation.

Svetlana G Vorsanova (SG)

Veltischev Research and Clinical Institute for Pediatrics, the Pirogov Russian National Research Medical University, Moscow, Russian Federation.

Yury B Yurov (YB)

Mental Health Research Center, Moscow, Russian Federation.

Tatyana V Zhilyaeva (TV)

Privolzhskiy Research Medical University, Nizhny Novgorod, Russian Federation.

Anzhelika V Sergeeva (AV)

Privolzhskiy Research Medical University, Nizhny Novgorod, Russian Federation.

Elena A Blokhina (EA)

First Saint Petersburg Pavlov State Medical University, Saint Petersburg, Russian Federation.

Edwin E Zvartau (EE)

First Saint Petersburg Pavlov State Medical University, Saint Petersburg, Russian Federation.

Anna S Blagonravova (AS)

Privolzhskiy Research Medical University, Nizhny Novgorod, Russian Federation.

Lyubomir I Aftanas (LI)

Federal State Scientific Budgetary Institution "Scientific Research Institute of Physiology and Basic Medicine,", Novosibirsk, Russian Federation.

Nikolay А Bokhan (NА)

Mental Health Research Institute, Tomsk National Research Medical Center of Russian Academy of Sciences, Tomsk, Russian Federation.
National Research Tomsk State University, Tomsk, Russian Federation.

Zurab I Kekelidze (ZI)

Serbsky National Medical Research Center on Psychiatry and Addictions, Moscow, Russian Federation.

Tatyana V Klimenko (TV)

Serbsky National Medical Research Center on Psychiatry and Addictions, Moscow, Russian Federation.

Irina P Anokhina (IP)

Serbsky National Medical Research Center on Psychiatry and Addictions, Moscow, Russian Federation.

Elza K Khusnutdinova (EK)

Institute of Biochemistry and Genetics, Ufa Federal Research Center, Russian Academy of Sciences, Ufa, Russian Federation.
Federal State Educational Institution of Highest Education Bashkir State Medical University of Public Health Ministry of Russian Federation, Ufa, Russian Federation.

Tatyana P Klyushnik (TP)

Mental Health Research Center, Moscow, Russian Federation.

Nikolay G Neznanov (NG)

V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology, Saint Petersburg, Russian Federation.

Vadim A Stepanov (VA)

Research Institute of Medical Genetics, Tomsk National Research Medical Center of Russian Academy of Sciences, Tomsk, Russian Federation.
National Research Tomsk State University, Tomsk, Russian Federation.

Thomas G Schulze (TG)

Institute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU, Munich, Germany.

Аleksandr О Kibitov (АО)

Serbsky National Medical Research Center on Psychiatry and Addictions, Moscow, Russian Federation.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH